image description
image description
Tell A Friend

FinancialNews


  • 23-05-17

    Oman-Neopharma issues OMR92mn in pharmaceutical plant

    (MENAFN) Neopharma, one of region's pioneering pharmaceutical manufacturing firms, has invested OMR92mn towards diabetes management in the GCC and global markets.

    Additionally, these investments involve OMR10mn in a state-of-the-art Japanese factory, OMR28mn in the acquisition of patents and licenses and an extra investment in clinical studies.

    Moreover, Neopharma Japan has obtained a 65 percent share in the Japanese pharmaceutical firm, Cosmo ALA to produce this dietary supplement.

    Accordingly, almost 422mn people are diabetic worldwide, while the number is projected to spiral to 642mn by 2040.

    MENAFN2305201700450000ID1095502651

Follow us

RSS
Terms & Conditions  |  Privacy & Security  |  Contact Us  | Sitemap
© 2024 BBK  |  All Rights Reserved